Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ACLX-001 |
Trade Name | |
Synonyms | ACLX001|ACLX 001 |
Drug Descriptions |
ACLX-001 is a cell therapy comprising SPRX-001, a soluble protein targeting TNFRSF17 (BCMA), and Antigen Receptor Complex T-cells (ARC T-cells), which potentially induces antitumor activity (Cancer Res (2021) 81 (13_Supplement): 1549). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ACLX-001 | ACLX-001 | 0 | 1 |
ACLX-001 + CART-ddBCMA | ACLX-001 CART-ddBCMA | 0 | 0 |